Demineralized Bone Matrix, BMP/Growth Factor, Bone Substitutes, Cell Based Matrices, Machined Bone, Allograft Bone, Platelet Concentrators, Traditional Fusion, Interbody Fusion, Inpatient and Outpatient Surgery Centers
The global Spine Biologics market is expected to grow at a moderate single digit growth rate over the forecast period. The global spine biologics market was valued at $2,997m in 2015. Visiongain forecasts this market to increase to $3,899m in 2020. The market will then continue to increase to $5,604m in 2026, growing at a CAGR 6.2% between 2020 and 2026.
How this report will benefit you: Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new report you find 142-page report you will receive 125 in-Depth charts – all unavailable elsewhere.
The 142 page report provides clear detailed insight into the global spine biologics market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope • Global Spine Biologics market forecasts from 2016-2026
• Spine biologics national market forecasts from 2016-2026, covering: – United States – Canada – Germany – France – United Kingdom – Italy – Spain – Russia – Rest of Europe – Japan – China – India – Australia – Rest of Asia-Pacific – Rest of the World
• Spine Biologics submarket forecasts from 2016-2026 covering:
– Revenue forecasts to 2026 are provided for the following segments in the spine biologics market, by product: • Demineralized Bone Matrix • BMP/Growth Factor • Bone Substitutes • Cell Based Matrices • Machined Bone • Allograft Bone • Platelet Concentrators
– Revenue forecasts to 2026 are provided for the following segments in the spine biologics market, by type of surgery: • Traditional Fusion • Interbody Fusion
– Revenue forecasts to 2026 are provided for the following segments in the spine biologics market, by end user: • Inpatient Surgery Centers • Outpatient Surgery Centers
• Analysis of the key factors driving growth in the global, regional and country level of spine biologics market from 2016-2026
• Assesses selected leading companies, examining recent performance and outlooks.
• Assessment of leading companies in the spine biologics market as well as strengths, weaknesses, opportunities, and threats in the market.
Visiongain’s study is intended for anyone requiring commercial analyses for the Spine Biologics Market and leading companies. You find data, trends and predictions.
Buy our report today Global Spine Biologics Market Forecast 2016-2026: Demineralized Bone Matrix, BMP/Growth Factor, Bone Substitutes, Cell Based Matrices, Machined Bone, Allograft Bone, Platelet Concentrators, Traditional Fusion, Interbody Fusion, Inpatient and Outpatient Surgery Centers.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Global Spine Biologics Market Overview 1.2 Why You Should Read This Report 1.3 How This Report Delivers 1.4 Who is This Report For? 1.5 Methodology 1.5.1 Primary Research 1.5.2 Secondary Research 1.5.3 Market Evaluation & Forecasting Methodology 1.6 Frequently Asked Questions (FAQ) 1.7 Associated Visiongain Reports 1.8 About Visiongain
2. Introduction to the Global Spine Biologics Market 2.1 Global Spine Biologics Market Structure 2.2 Spine Biologics Market Definition 2.3 Spine Biologics Submarkets Definition 2.3.1 Demineralized Bone Matrix Submarket Definition 2.3.2 BMP/Growth Factors Submarket Definition 2.3.3 Bone Substitutes Submarket Definition 2.3.4 Cell Based Matrices Submarket Definition 2.3.5 Machined Bones Submarket Definition 2.3.6 Allograft Bones Submarket Definition 2.4 Regulations for Biologics
3. Global Spine Biologics Market 2016-2026 3.1 Global Spine Biologics Market Forecast 2016-2026 3.2 Global Spine Biologics Drivers & Restraints 2016
4. Spine Biologics Market by Product 2016-2026 4.1 Introduction 4.2 Demineralized Bone Matrix (DBM) Market 2016-2026 4.3 BMP/Growth Factors Market 2016-2026 4.4 Bone Substitutes Market 2016-2026 4.5 Cell Based Matrices Market 2016-2026 4.6 Machined Bone Market 2016-2026 4.7 Allograft Bone Market 2016-2026 4.8 Platelet Concentrators Market 2016-2026 4.9 Other Spine Biologics Market 2016-2026
5. Spine Biologics Market by Type of Surgery 2016-2026 5.1 Introduction 5.2 Traditional Fusion Market 2016-2026 5.3 Interbody Fusion Market 2016-2026
6. Spine Biologics Market by End Users 2016-2026 6.1 Introduction 6.2 Inpatient Surgery Spine Centers 2016-2026 6.3 Outpatient Surgery Spine Centers 2016-2026
7. Leading National Markets 2016-2026 7.1 Introduction 7.2 North America Spine Biologics Market 2016-2026 7.2.1 U.S. Spine Biologics Market 2016-2026 7.2.2 Canada Spine Biologics Market 2016-2026 7.3 Europe Spine Biologics Market 2016-2026 7.3.1 Germany Spine Biologics Market 2016-2026 7.3.2 U.K. Spine Biologics Market 2016-2026 7.3.3 France Spine Biologics Market 2016-2026 7.3.4 Italy Spine Biologics Market 2016-2026 7.3.5 Spain Spine Biologics Market 2016-2026 7.3.6 Russia Spine Biologics Market 2016-2026 7.3.7 Rest of Europe Spine Biologics Market 2016-2026 7.4 Asia-Pacific Spine Biologics Market 2016-2026 7.4.1 Japan Spine Biologics Market 2016-2026 7.4.2 China Spine Biologics Market 2016-2026 7.4.3 India Spine Biologics Market 2016-2026 7.4.4 Australia Spine Biologics Market 2016-2026 7.4.5 Rest of Asia-Pacific Spine Biologics Market 2016-2026 7.5 Rest of the World (RoW) Spine Biologics Market 2016-2026
8. Leading Companies in the Spine Biologics Market, 2016-2026 8.1 Spine Biologics: 8.2 Medtronic plc 8.2.1 Medtronic Product Portfolio, 2015 8.2.2 Medtronic plc: Historical and Performance Analysis 8.2.3 Medtronic plc: Recent Developments 8.2.3.1 U.S. FDA Approval - Infuse Bone Graft 8.2.3.2 Acquistion of Osteotech Inc. 8.3 SeaSpine Holdings Corporation 8.3.1 SeaSpine Product Portfolio, 2015 8.3.2 SeaSpine: Historical and Performance Analysis 8.3.3 SeaSpine Holdings Corporation: Recent Developments 8.4 DePuy Synthes (a business segment of Johnson & Johnson) 8.4.1 DePuy Synthes: Product Portfolio, 2015 8.4.2 JOHNSON & JOHNSON: Historical and Performance Analysis 8.4.3 DePuy Synthes: Recent Developments 8.4.3.1 Introduction of VIVIGEN CELLULAR BONE MATRIX 8.4.3.2 Agreement with LifeNet Health (U.S.) 8.4.3.3 Launched New Tissue Implant-CONFORM SHEET 8.5 Stryker Corporation 8.5.1 Stryker Corporation Product Portfolio, 2015 8.5.2 Stryker Corporation: Historical and Performance Analysis 8.5.3 Stryker Corporation: Recent Developments 8.5.3.1 Introduction of Next Generation Viable Bone Matrix 8.5.3.2 Strategic Partnership with Osiris 8.5.3.3 Accellos’ Warehouse Management System 8.5.3.4 Acqusition of Orthovita Inc 8.6 GLOBUS MEDICAL, INC. 8.6.1 GLOBUS MEDICAL, INC.Product Portfolio, 2015 8.6.2 GLOBUS MEDICAL, INC.: Historical and Performance Analysis 8.6.3 GLOBUS MEDICAL, INC.: Recent Developments 8.6.3.1 Acquistion of Alphatec’s International Business 8.6.3.2 Acquistion of Transplant Technologies of Texas, Ltd. (TTOT) 8.7 Zimmer Biomet Holdings, Inc. 8.7.1 Zimmer Biomet Holdings, Inc.Product Portfolio, 2015 8.7.2 Zimmer Biomet Holdings, Inc.: Historical and Performance Analysis 8.7.3 Zimmer Biomet Holdings, Inc.: Recent Developments 8.7.3.1 Distribution Agreement with CelgenTek Innovations Corporation 8.7.3.2 Acquistion Biomet, Inc. 8.8 NuVasive, Inc. 8.8.1 NuVasive Inc.Product Portfolio, 2015 8.8.2 NuVasive, Inc.: Historical and Performance Analysis 8.8.3 NuVasive, Inc.: Recent Developments 8.8.3.1 Launch of Next Generation Biologics Technology 8.9 Alphatec Holdings, Inc. 8.9.1 Alphatec Holdings, Inc..Product Portfolio, 2015 8.9.2 Alphatec Holdings, Inc.: Historical and Performance Analysis 8.9.3 Alphatec Holdings, Inc.: Recent Developments 8.9.3.1 Launch of Neocore(TM) Osteoconductive Matrix
9. SWOT Analysis of the Spine Biologics Market 9.1 Strengths 9.1.1 Evolving Regulatory Framework 9.1.2 Technological Innovations in Biomaterials 9.1.3 Initiatives and Supports from the Governments 9.2 Weaknesses 9.2.1 The High Cost of Spine Biologics Products 9.2.2 Lack of Funding from Venture Capital 9.2.3 Lack of Standardisation in Manufacturing Process 9.2.4 New Business Models are yet to be Established 9.3 Opportunities 9.3.1 Development of 3D Printed Bone Grafts and Other Innovative Technology 9.3.2 Rising Trend of Medical Tourism in Emerging Countries 9.3.3 Growing Number of Spine Surgery Centers and Hospitals 9.4 Threats 9.4.1 Ethical Concerns Limiting Research and Development in Spine Biologics 9.4.2 Scarcity of Skilled Physicians in Emerging Countries
10. Conclusions and Recommendations 10.1 Overview of the Spine Biologics Market 10.2 Leading Spine Biologics Segments in 2016 and 2026 10.2 Leading Spine Biologics Market by Region in 2016 and 2026 10.3 Future Outlook for Spine Biologics Market
Visiongain Report Evaluation Form Associated Visiongain Reports Visiongain Report Sales Order Form About Visiongain Visiongain Report Evaluation Form
List of Tables Table 1.1 (Sample) Global Spine Biologics Market by Region: Market Forecast ($m), AGR (%), CAGR (%), 2014-2020 Table 3.1 Global Spine Biologics Market Forecast ($m), AGR(%),CAGR(%), 2014-2020 Table 3.2 Global Spine Biologics Market Forecast ($m), AGR(%),CAGR(%), 2020-2026 Table 3.3 Global Spine Biologics Market Drivers & Restraints, 2016 Table 4.1 DBM Market Forecast ($m), AGR(%),CAGR(%), 2016-2026 Table 4.2 BMP/Growth Factors Market Forecast ($m), AGR(%),CAGR(%), 2016-2026 Table 4.3 Bone Substitutes Market Forecast ($m), AGR(%),CAGR(%), 2016-2026 Table 4.4 Cell Based Matrices Market Forecast ($m), AGR(%),CAGR(%), 2016-2026 Table 4.5 Machined Bone Market Forecast ($m), AGR(%),CAGR(%), 2016-2026 Table 4.6 Allograft Bone Market Forecast ($m), AGR(%),CAGR(%), 2016-2026 Table 4.7 Platelet Concentrators Market Forecast ($m), AGR(%),CAGR(%), 2016-2026 Table 4.8 Other Spine Biologics Market Forecast ($m), AGR(%),CAGR(%), 2016-2026 Table 5.1 Spine Biologics Market by Type of Surgery: Market Forecast ($m), AGR(%),CAGR(%), 2014-2020 Table 5.2 Spine Biologics Market by Type of Surgery: Market Forecast ($m), AGR(%),CAGR(%), 2020-2026 Table 5.3 Traditional Fusion Market Forecast ($m), AGR(%),CAGR(%), 2016-2026 Table 5.4 Interbody Fusion Market Forecast ($m), AGR(%), CAGR(%), 2016-2026 Table 6.1 Spine Biologics Market by End User: Market Forecast ($m), AGR(%), CAGR(%), 2014-2020 Table 6.2 Spine Biologics Market by End User: Market Forecast ($m), AGR(%), CAGR(%), 2020-2026 Table 6.3 Inpatient Surgery Spine Centers Market Forecast ($m), AGR(%), CAGR(%), 2016-2026 Table 6.4 Outpatient Surgery Spine Centers Market Forecast ($m), AGR(%), CAGR(%), 2016-2026 Table 7.1 World Spine Biologics Market by Region: Revenues ($m) and Market Share (%), 2015 and 2016 Table 7.2 Global Spine Biologics Market by Region: Market Forecast ($m), AGR(%), CAGR(%), 2014-2020 Table 7.3 Global Spine Biologics Market by Region: Market Forecast ($m), AGR(%), CAGR(%), 2020-2026 Table 7.4 North America Spine Biologics Market: Revenues ($m) and Market Share (%), 2015 and 2016 Table 7.5 North America Spine Biologics Market: Market Forecast ($m), AGR(%), CAGR(%), 2014-2020 Table 7.6 North America Spine Biologics Market: Market Forecast ($m), AGR(%), CAGR(%), 2020-2026 Table 7.7 Europe Spine Biologics Market: Revenues ($m) and Market Share (%), 2015 and 2016 Table 7.8 Europe Spine Biologics Market: Market Forecast ($m), AGR(%), CAGR(%), 2014-2020 Table 7.9 Europe Spine Biologics Market: Market Forecast ($m), AGR(%), CAGR(%), 2020-2026 Table 7.10 Asia-Pacific Spine Biologics Market: Revenues ($m) and Market Share (%), 2015 and 2016 Table 7.11 Asia-Pacific Spine Biologics Market: Market Forecast ($m), AGR(%), CAGR(%), 2014-2020 Table 7.12 Asia-Pacific Spine Biologics Market: Market Forecast ($m), AGR(%), CAGR(%), 2020-2026 Table 8.1 Medtronic ($m, 2011-2015) Table 8.2 Medtronic plc: Revenue by Business Segment ($m), 2014-2015 Table 8.3 Medtronic plc: Revenue by Geographic Segment ($m), 2014-2015 Table 8.4 SeaSpine Holdings Corporation ($m, 2012-2015) Table 8.5 SeaSpine Holdings Corporation: Revenue by Business Segment ($m), 2014-2015 Table 8.6 SeaSpine Holdings Corporation: Revenue by Geographic Segment ($m), 2014-2015 Table 8.7 JOHNSON & JOHNSON ($m, 2011-2015) Table 8.8 JOHNSON & JOHNSON: Revenue by Business Segment ($m), 2014-2015 Table 8.9 JOHNSON & JOHNSON: Revenue by Geographic Segment ($m), 2014-2015 Table 8.10 Stryker Corporation ($m, 2011-2015) Table 8.11 Stryker Corporation: Revenue by Business Segment, ($m, 2014-2015) Table 8.12 Stryker Corporation: Revenue by Geographic Segment, ($m, 2014-2015) Table 8.13 GLOBUS MEDICAL, INC. ($m, 2011-2015) Table 8.14 GLOBUS MEDICAL, INC.: Revenue by Business Segment, ($m, 2014-2015) Table 8.15 GLOBUS MEDICAL, INC.: Revenue by Geographic Segment, ($m, 2014-2015) Table 8.16 ZIMMER BIOMET HOLDINGS, INC. ($m, 2013-2015) Table 8.17 ZIMMER BIOMET HOLDINGS, INC.: Revenue by Business Segment ($m), 2014-2015 Table 8.18 ZIMMER BIOMET HOLDINGS, INC.: Revenue by Geographic Segment, ($m,2014-2015) Table 8.19 NuVasive, Inc. ($m, 2013-2015) Table 8.20 NuVasive, Inc.: Revenue by Business Segment, ($m,2014-2015) Table 8.21 NuVasive, Inc.: Revenue by Geographic Segment, ($m,2014-2015) Table 8.22 Alphatec Holdings, Inc.. ($m, 2011-2015) Table 8.23 Alphatec Holdings, Inc.: Revenue by Geographic Segment, ($m,2014-2015) Table 10.1 Global Spine Biologics: Market Forecast ($m, CAGR%), 2015, 2020 and 2026 Table 10.2 Global Spine Biologics Market by Type of Products : Revenues ($m) and Market Shares (%), 2015
List of Figures Figure 1.1 Global Spine Biologics Market Segmentation Figure 3.1 Global Spine Biologics Market Forecast ($m), AGR(%), 2015-2016 Figure 4.1 Spine Biologics Market Share (%) by Segment, 2020 Figure 4.2 Spine Biologics Market Share (%) by Segment, 2026 Figure 4.3 DBM Market Forecast: Revenue ($m) and AGR (%), 2015-2026 Figure 4.5 BMP/Growth Factors Market Forecast: Revenue ($m) and AGR (%), 2015-2026 Figure 4.6 Bone Substitutes Market Forecast: Revenue ($m) and AGR (%), 2015-2026 Figure 4.7 Cell Based Matrices Market Forecast: Revenue ($m) and AGR (%), 2015-2026 Figure 4.8 Machined Bone Market Forecast: Revenue ($m) and AGR (%), 2015-2026 Figure 4.9 Allograft Bone Market Forecast: Revenue ($m) and AGR (%), 2015-2026 Figure 4.10 Platelet Concentrators Market Forecast: Revenue ($m) and AGR (%), 2015-2026 Figure 4.11 Other Spine Biologics Market Forecast: Revenue ($m) and AGR (%), 2015-2026 Figure 5.1 Spine Biologics Market Share (%) by Segment, 2015 Figure 5.2 Spine Biologics Market Share (%) by Segment, 2020 Figure 5.3 Spine Biologics Market Share (%) by Segment, 2026 Figure 5.4 Traditional Fusion Market Forecast: Revenue ($m) and AGR (%), 2015-2026 Figure 5.5 Interbody Fusion Market Forecast: Revenue ($m) and AGR (%), 2015-2026 Figure 6.1 Spine Biologics Market Share (%)by Segment, 2015 Figure 6.2 Spine Biologics Market Share (%)by Segment, 2020 Figure 6.3 Spine Biologics Market Share (%)by Segment, 2026 Figure 6.4 Inpatient Surgery Spine Centers Market Forecast: Revenue ($m) and AGR (%), 2015-2026 Figure 6.5 Outpatient Surgery Spine Centers Market Forecast: Revenue ($m) and AGR (%), 2015-2026 Figure 7.1 Global Spine Biologics Market by Region: Market Size ($m), 2015 and 2016 Figure 7.2 US Spine Biologics Market Forecast ($m), AGR(%), 2015-2026 Figure 7.3 Canada Spine Biologics Market Forecast ($m), AGR(%), 2015-2026 Figure 7.4 Germany Spine Biologics Market Forecast ($m), AGR(%), 2015-2026 Figure 7.5 UK Spine Biologics Market Forecast ($m), AGR(%), 2015-2026 Figure 7.6 France Spine Biologics Market Forecast ($m), AGR(%), 2015-2026 Figure 7.7 Italy Spine Biologics Market Forecast ($m), AGR(%), 2015-2026 Figure 7.8 Spain Spine Biologics Market Forecast ($m), AGR(%), 2015-2026 Figure 7.9 Russia Spine Biologics Market Forecast ($m), AGR(%), 2015-2026 Figure 7.10 Rest of Europe Spine Biologics Market Forecast ($m), AGR(%), 2015-2026 Figure 7.11 Asia Pacific Spine Biologics Market Forecast ($m), AGR(%), 2015-2026 Figure 7.12 Japan Spine Biologics Market Forecast ($m), AGR(%), 2015-2026 Figure 7.13 China Spine Biologics Market Forecast ($m), AGR(%), 2015-2026 Figure 7.14 India Spine Biologics Market Forecast ($m), AGR(%), 2015-2026 Figure 7.15 Australia Spine Biologics Market Forecast ($m), AGR(%), 2015-2026 Figure 7.16 Rest of Asia-Pacific Spine Biologics Market Forecast ($m), AGR(%), 2015-2026 Figure 7.17 RoW Spine Biologics Market Forecast ($m), AGR(%), 2015-2026 Figure 8.1 Global Spine Biologics Market Share, By Companies (% share, 2015) Figure 8.2 Medtronic plc: Historical sales and net income ($m), 2011-2015 Figure 8.3 Medtronic plc: Revenue Share by Business Area, (%, 2015) Figure 8.4 Medtronic plc: Revenue Share by Geographic Segment (%, 2015) Figure 8.5 SeaSpine Holdings Corporation: Historical sales and net income ($m), 2012-2015 Figure 8.6 SeaSpine Holdings Corporation: Revenue Share by Business Segment (%, 2015) Figure 8.7 SeaSpine Holdings Corporation: Revenue Share by Geographic Segment (%, 2015) Figure 8.8 JOHNSON & JOHNSON: Historical sales and net income, 2011-2015 Figure 8.9 JOHNSON & JOHNSON: Revenue Share by Business Segment (%, 2015) Figure 8.10 JOHNSON & JOHNSON: Revenue Share by Geographic Segment (%, 2015) Figure 8.11 Stryker Corporation: Historical sales and net income, 2011-2015 Figure 8.12 Stryker Corporation: Revenue Share by Business Segment, (%, 2015) Figure 8.13 Stryker Corporation: Revenue Share by Geographic Segment (%, 2015) Figure 8.14 GLOBUS MEDICAL, INC.: Historical sales and net income ($m), 2011-2015 Figure 8.15 GLOBUS MEDICAL, INC.: Revenue Share by Business Segment, (%, 2015) Figure 8.16 GLOBUS MEDICAL, INC.: Revenue Share by Geographic Segment (%, 2015) Figure 8.17 ZIMMER BIOMET HOLDINGS, INC.: Historical sales and net income ($m), 2013-2015 Figure 8.18 ZIMMER BIOMET HOLDINGS, INC.: Revenue Share by Business Segment, (%, 2015) Figure 8.19 ZIMMER BIOMET HOLDINGS, INC.: Revenue Share by Geographic Segment (%, 2015) Figure 8.20 NuVasive, Inc.: Historical sales and net income ($m), 2013-2015 Figure 8.21 NuVasive, Inc.: Revenue Share by Business Segment, (%, 2015) Figure 8.22 NuVasive, Inc.: Revenue Share by Geographic Segment (%, 2015) Figure 8.23 Alphatec Holdings, Inc.: Historical sales and net income ($m), 2011-2015 Figure 8.24 Alphatec Holdings, Inc.: Revenue Share by Geographic Segment (%, 2015) Figure 10.1 Global Spine Biologics: Market Forecast ($m) 2015, 2020 and 2026 Figure 10.2 Global Spine Biologics Market by Type of Products: 2016 ($m) Figure 10.3 Global Spine Biologics Market by Type of Products: 2026 ($m) Figure 10.4 Global Spine Biologics Market by Geography: 2016 ($m) Figure 10.5 Global Spine Biologics Market by Geography: 2026 ($m)
Alphatec Holdings, Inc. Biomet, Inc. CelgenTek Innovations Corporation Chinese Academy of Sciences Covidein plc DePuy Synthes EMA FDA Globus Medical, Inc. Indo UK Institute of Health (IUIH) Integra LifeSciences Holdings Corporation Japanese Health Ministry Johnson & Johnson LifeNet Health Medtronic plc Mega Surgical NuVasive, Inc. Orthovita Inc. Osiris Therapeutics, Inc. SeaSpineHoldings, Inc. Stryker Corporation Therapure Biopharma Transplant Technologies of Texas, Ltd. Weizmann Institute of Science Zimmer Biomet Holdings, Inc. Zimmer, Inc.
Download sample pages
Complete the form below to download your free sample pages for Global Spine Biologics Market Forecast 2016-2026
Download sample pages
Complete the form below to download your free sample pages for Global Spine Biologics Market Forecast 2016-2026
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions.
Visiongain Publishes Next Generation Sequencing Market Report 2021-2031
Rising preference for personalised medicine in developed as well as developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase NGS market concentration over the forecast period.
The rising frequency of bacterial and viral diseases coupled with increased focus on immunisation programmes are two main reasons that are expected to boost the global anti-infective vaccines market’s growth in the coming years.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
